GENE ONLINE|News &
Opinion
Blog

Jazz Pharmaceuticals
Jazz Opts Into License Zymeworks’ Solid Tumor Med With $325 Million Payment
2022-12-21
Jazz Pharma’s Xywav Becomes First FDA Approved Drug for a Rare Neurologic Disease
2021-08-13
FDA Approves Jazz Pharma’s Rylaze for Treating Common Leukemia in Children
2021-07-04
R&D
SCLC Treatment Gets a Boost as PharmaMar’s Lurbinectedin Bags Priority Review Status
2020-02-19
LATEST
BioNTech’s Bold Move: Rwanda’s New mRNA Vaccine Factory Set to Boost African Healthcare
2024-11-06
Global Trade Wars and Innovation Shake Up the Life Sciences Industry
2024-11-06
Antibody-Drug Conjugates: Connecting Drugs to Cancer Cells and Unlocking Billions in Market Opportunities
2024-11-06
Driving Post-Pandemic Growth: Navigating Pricing Pressures and the Rise of Generative AI
2024-11-06
Biotech on the Ballot: How the U.S. Presidential Election Puts Industry Policy to the Test
2024-11-06
The Golden Age of Medicine: Advancements in Novel Modalities and Therapeutic Areas
2024-11-01
Strengthening Biotech Ties: Highlights from the BioConnect Forum and Future Collaboration between Taiwan and Australia
2024-10-31
EVENT
Scroll to Top